chronic lymphocytic leukaemia Archives -

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence data

Phil Taylor AbbVie, AstraZeneca, BeiGene, Brukinsa, Calquence, chronic lymphocytic leukaemia, Haematology, Imbruvica, Johnson & Johnson, Oncology 0 Comment

AstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence data

https://pharmaphorum.com/news/asco21-az-seeks-to-supplant-imbruvica-in-cll-with-new-calquence-data/

News/ News/ Oncology

TG Therapeutics completes FDA filing for Roche challenger in CLL

Richard Staines blood cancer, chronic lymphocytic leukaemia, Roche, TG Therapeutics 0 Comment

TG Therapeutics has completed its rolling FDA filing for its U2 combination therapy consisting of the antibody ublituximab

TG Therapeutics completes FDA filing for Roche challenger in CLL

https://pharmaphorum.com/news/tg-therapeutics-completes-fda-filing-for-roche-challenger-in-cll/

Market Access/ News/ News

NICE backs AZ’s Calquence for new use in leukaemia

Phil Taylor AstraZeneca, Calquence, cholesterol, chronic lymphocytic leukaemia, Daiichi Sankyo, NHS, NICE, Nilemdo 0 Comment

AstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS

NICE backs AZ’s Calquence for new use in leukaemia

https://pharmaphorum.com/news/nice-backs-azs-calquence-for-new-use-in-leukaemia/

News/ News/ Oncology

AZ says Calquence is a safer drug than Imbruvica

Phil Taylor AbbVie, AstraZeneca, BTK inhibitor, Calquence, chronic lymphocytic leukaemia, Imbruvica, Johnson & Johnson, Oncology 0 Comment

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment

AZ says Calquence is a safer drug than Imbruvica

https://pharmaphorum.com/news/az-says-calquence-is-a-safer-drug-than-imbruvica/

Stock brokers looking at computer screens, trading online.

News/ News/ Oncology

TG Therapeutics raises funds for cancer combination drug

Richard Staines chronic lymphocytic leukaemia, Oncology, TG Therapeutics 0 Comment

TG Therapeutics provided one of the highlights of the American Society of Hematology (ASH) conference earlier this month

TG Therapeutics raises funds for cancer combination drug

https://pharmaphorum.com/news/tg-therapeutics-set-for-upsized-ipo-to-develop-cancer-combination-drug/

Market Access/ News/ News

CLL patients in England to get AZ’s Calquence after okay from NICE

Richard Staines AstraZeneca, chronic lymphocytic leukaemia, market access, NICE 0 Comment

NHS England is to grant immediate access to AstraZeneca’s cancer drug Calquence (acalabrutinib) for certain patients with chronic

CLL patients in England to get AZ’s Calquence after okay from NICE

https://pharmaphorum.com/news/cll-patients-in-england-to-get-azs-calquence-after-okay-from-nice/

News/ News/ Oncology

TG Therapeutics challenges Roche with FDA filing for CLL drug

Richard Staines blood cancer, chronic lymphocytic leukaemia, CLL, fda, Roche, TG Therapeutics 0 Comment

US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic

TG Therapeutics challenges Roche with FDA filing for CLL drug

https://pharmaphorum.com/news/tg-therapeutics-challenges-roche-with-fda-filing-for-cll-drug/

Market Access/ News/ News/ Top stories

NICE backs chemo-free CLL combination from AbbVie and Roche

Richard Staines AbbVie, cancer, chronic lymphocytic leukaemia, market access, Roche 0 Comment

Previously untreated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE

NICE backs chemo-free CLL combination from AbbVie and Roche

https://pharmaphorum.com/news/nice-backs-chemo-free-cll-combination-from-abbvie-and-roche/

Market Access/ News/ News/ News/ Oncology

AbbVie, J&J embed Imbruvica deeper in CLL therapy with new approval

Phil Taylor AbbVie, chronic lymphocytic leukaemia, Imbruvica, Johnson & Johnson, Oncology 0 Comment

AbbVie and Johnson & Johnson’s Imbruvica is already a mainstay of chronic lymphocytic leukaemia (CLL) therapy, but can

AbbVie, J&J embed Imbruvica deeper in CLL therapy with new approval

https://pharmaphorum.com/news/abbvie-jj-embed-imbruvica-deeper-in-cll-therapy-with-new-approval/

Trending

chronic lymphocytic leukaemia

Login